【公司盈警】四环医药(00460)料2024全年亏损至多6亿元人民币

金吾财讯
04 Feb

金吾财讯 | 四环医药(00460)公布,集团预期截至2024年12月31日止年度取得不低于人民币18亿元的收入及不超过人民币6亿元的亏损。影响集团于该年度内的财务业绩主要包括如下因素:(1)集团的仿制药业务受国家集采政策的影响持续走低;(2)集团的医美业务延续2024年上半年的走势,保持了不低于50%的高速增长;(3)集团的创新药研发进入中后期阶段,尽管研发开支较以往有所下降,但为了保证产品的快速推进,集团对创新药的研发开支仍然保持较高的水平;及(4)公司的附属公司轩竹生物科技股份有限公司于该年度新授予股权激励产生的一次性费用。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10